ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
Dr. Meyrick brings more than 20 years of medical research, radiotheranostic drug development and management experience to ITM.
- Dr. Meyrick brings more than 20 years of medical research, radiotheranostic drug development and management experience to ITM.
- Before joining ITM, Dr. Meyrick was Chief Scientific Officer, Research and Insights at GenesisCare where she spearheaded medical and clinical strategies with a focus on radiopharmaceutical development.
- Dr. Meyrick also served as the consulting Chief Medical Officer at AdvanCell Isotopes where she led clinical development efforts across pipeline assets.
- As Chief Medical Officer, APAC and Global Head of Clinical Science at Telix Pharmaceuticals, Dr. Meyrick oversaw the clinical development of theranostic radiopharmaceutical candidates in the Asia Pacific region and supported commercial strategic planning efforts.